RESUMEN

The standard regimen for the treatment of chronic hepatitis C virus (HCV) is peginterferon alpha-2a or -2b associated with ribavirine. The recommended duration of treatment for genotype 2 HCV infection is 24 weeks. However, the relatively poor drug tolerance often leads to a reduction or a discontinuation of the treatment. Here, we report two female patients who discontinued antiviral therapy after less than 6 weeks for intolerance and who experienced a sustained virological response. A treatment of 3 to 5 weeks may be enough for genotype 2 HCV eradication. However, there is not sufficient evidence in 2009 to recommend a reduced treatment duration.

Asunto(s)

Hepatitis C Crónica/tratamiento farmacológico , Antivirales/uso terapéutico , ADN Viral/análisis , Femenino , Hepatitis C Crónica/genética , Humanos , Interferón alfa-2 , Interferón-alfa/uso terapéutico , Cumplimiento de la Medicación , Persona de Mediana Edad , Polietilenglicoles/uso terapéutico , Proteínas Recombinantes , Ribavirina/uso terapéutico

Asunto(s)

Várices Esofágicas y Gástricas/complicaciones , Fármacos Gastrointestinales/farmacocinética , Hemorragia Gastrointestinal/prevención & control , Octreótido/farmacocinética , Humanos , Infusiones Intravenosas , Inyecciones Subcutáneas , Masculino , Octreótido/administración & dosificación , Recurrencia